Prophylaxis with isavuconazole or posaconazole protects immunosuppressed mice from pulmonary mucormycosis

Teclegiorgis Gebremariam, Sondus Alkhazraji, Clara Baldin, Laura Kovanda, Nathan Wiederhold, Ashraf S. Ibrahim

Research output: Contribution to journalArticle

6 Scopus citations

Abstract

We assessed prophylactic or continuous therapy of isavuconazole, posaconazole, or voriconazole in treating pulmonary murine mucormycosis. In the prophylaxis studies, only isavuconazole treatment resulted in significantly improved survival and lowered tissue fungal burden of immunosuppressed mice infected with Rhizopus delemar. In the continuous treatment studies, isavuconazole and posaconazole, but not voriconazole, equally prolonged survival time and lowered tissue fungal burden compared to placebo-treated mice. These results support the use of isavuconazole and posaconazole in prophylaxis treatment.

Original languageEnglish (US)
Article numbere02589
JournalAntimicrobial Agents and Chemotherapy
Volume61
Issue number5
DOIs
StatePublished - May 1 2017

    Fingerprint

Keywords

  • Isavuconazole
  • Mucormycosis
  • Murine
  • Posaconazole
  • Prophylaxis
  • Rhizopus delemar
  • Voriconazole

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Gebremariam, T., Alkhazraji, S., Baldin, C., Kovanda, L., Wiederhold, N., & Ibrahim, A. S. (2017). Prophylaxis with isavuconazole or posaconazole protects immunosuppressed mice from pulmonary mucormycosis. Antimicrobial Agents and Chemotherapy, 61(5), [e02589]. https://doi.org/10.1128/AAC.02589-16